semaglutide .25 mg weight loss Oral Wegovy approved for obesity management by FDA on December 23, 2025 Formulation: High‑dose oral (25 daily) — previously only available as weekly injections. Indication: Adults with obesity (BMI ≥30) Wegovy (semaglutide) Injector 0.25 mg/0.5

Genetically susceptible follicles, particularly those at the crown and temples, possess higher concentrations of androgen receptors, making them more vulnerable to DHT-induced damage

In a powerful speech against colorism (prejudice against skin colour) in 2014, she spoke about being taunted for her dark skin and of how narrow standards of beauty affected her self esteem when she was younger

Cardiovascular: Cytoprotective effects in myocardial infarction and arrhythmia models

Minor and repetitive head injury

Effects of SDF-1/CXCR4 on the repair of traumatic brain injury in rats by mediating bone marrow derived Mesenchymal stem cells

the drug is subject to an open drug efficacy study, health care professionals rely on the drug to treat serious medical conditions when there is no FDA-approved drug to treat the condition, and there is insufficient supply of an FDA-approved drug